| SC 13D/A | 2021-11-19 | Growth Equity Opportunities V, LLC | Trillium Therapeutics Inc. | - | - | EDGAR |
| SC 13G/A | 2021-11-15 | RA CAPITAL MANAGEMENT, L.P. | Trillium Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2021-09-01 | Growth Equity Opportunities V, LLC | Trillium Therapeutics Inc. | 6,586,363 | 6.3% | EDGAR |
| SC 13G/A | 2021-04-07 | RA CAPITAL MANAGEMENT, L.P. | Trillium Therapeutics Inc. | 5,290,481 | 5.1% | EDGAR |
| SC 13G/A | 2021-02-16 | Venrock Healthcare Capital Partners III, L.P. | Trillium Therapeutics Inc. | 4,040,000 | 4.0% | EDGAR |
| SC 13G/A | 2021-02-16 | Boxer Capital, LLC | Trillium Therapeutics Inc. | - | 0.0% | EDGAR |
| SC 13G | 2021-02-16 | RA CAPITAL MANAGEMENT, L.P. | Trillium Therapeutics Inc. | 5,290,481 | 5.3% | EDGAR |
| SC 13G/A | 2021-02-12 | Vivo Capital IX, LLC | Trillium Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2021-02-12 | Avoro Capital Advisors LLC | Trillium Therapeutics Inc. | 5,800,000 | 5.7% | EDGAR |
| SC 13G/A | 2020-05-11 | MORGAN STANLEY | Trillium Therapeutics Inc. | 1,243,313 | 1.5% | EDGAR |
| SC 13G/A | 2020-02-14 | Matrix Capital Management Company, LP | Trillium Therapeutics Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2020-02-14 | Sio Capital Management, LLC | Trillium Therapeutics Inc. | 2,751,186 | 9.8% | EDGAR |
| SC 13G/A | 2020-02-13 | MORGAN STANLEY | Trillium Therapeutics Inc. | 1,870,004 | 6.7% | EDGAR |
| SC 13D/A | 2020-02-04 | Growth Equity Opportunities V, LLC | Trillium Therapeutics Inc. | 6,586,363 | 8.7% | EDGAR |
| SC 13G | 2020-02-03 | Boxer Capital, LLC | Trillium Therapeutics Inc. | 4,425,000 | 5.9% | EDGAR |
| SC 13G | 2020-02-03 | Vivo Capital IX, LLC | Trillium Therapeutics Inc. | 820,940 | 1.1% | EDGAR |
| SC 13G/A | 2020-01-21 | Empery Asset Management, LP | Trillium Therapeutics Inc. | 4,495,239 | 5.0% | EDGAR |
| SC 13G | 2020-01-21 | Venrock Healthcare Capital Partners III, L.P. | Trillium Therapeutics Inc. | 2,790,000 | 10.0% | EDGAR |
| SC 13G | 2019-12-31 | MORGAN STANLEY | Trillium Therapeutics Inc. | 1,649,478 | 5.9% | EDGAR |
| SC 13D/A | 2019-03-04 | Growth Equity Opportunities V, LLC | Trillium Therapeutics Inc. | 2,123,910 | 10.0% | EDGAR |